NCT07320417 is a NA clinical trial of chneiderian Membrane-Preserving in Maxillary Diseases, sponsored by Wenzhao Guan.

Who is sponsoring NCT07320417?

NCT07320417 is sponsored by Wenzhao Guan.

What drugs are being tested in NCT07320417?

Interventions in NCT07320417: chneiderian Membrane-Preserving.

What condition does NCT07320417 study?

NCT07320417 studies Maxillary Diseases.

Is NCT07320417 still recruiting?

NCT07320417 is currently recruiting now. Last updated 27 January 2026.

Last reviewed 2026-01-27 · How we verify

NCT07320417

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Schneider Membrane Preservation With In Situ Osteogenesis: A Modified Maxillary Resection Study

Recruiting now NA Last updated 27 January 2026

What this trial tests

NA trial testing chneiderian Membrane-Preserving in Maxillary Diseases in 18 participants. Currently enrolling.

Timeline

1 May 2025

Primary endpoint
8 June 2026

10 June 2026

Quick facts

Lead sponsor	Wenzhao Guan
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	1 May 2025
Primary completion	8 June 2026
Estimated completion	10 June 2026
Sites	1 location across China

Drugs / interventions tested

chneiderian Membrane-Preserving

Conditions studied

Maxillary Diseases — all drugs for Maxillary Diseases →

Sponsor

Wenzhao Guan

Who can join

Adults 18 to 75, any sex, with Maxillary Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This case series study aimed to find out if a new surgical technique that preserves the sinus membrane during upper jaw removal can help patients regenerate bone and recover function better after surgery. The study included two female patients with jaw tumors who were not suitable for or did not want complex reconstruction with tissue flaps. The main questions the study tried to answer were: Can the preserved sinus membrane help new bone grow spontaneously in the jaw defect area after surgery? Can this new method reduce common complications seen with traditional surgery, such as oronasal fistula and empty nose syndrome? How well can patients recover in terms of chewing, swallowing, speech, and quality of life after the procedure? In the study, during surgery, the surgeon carefully separated and preserved the sinus membrane from the bone that needed to be removed. After surgery, patients were followed with regular CT scans to check new bone growth. They also underwent tests to measure chewing force, swallowing ability, speech function, and quality of life to evaluate the long-term outcomes of this technique.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07320417 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wenzhao Guan
Last refreshed: 27 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07320417.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing